TY - JOUR
T1 - Outcome of diffuse large B-cell lymphoma in the united states has improved over time but racial disparities remain
T2 - Review of SEER data
AU - Komrokji, Rami S.
AU - Al Ali, Najla H.
AU - Beg, M. S.
AU - Safa, Malek M.
AU - Rollison, Dana
AU - Kharfan-Dabaja, Mohamed
AU - Bello, Celeste
AU - Cultrera, Jennifer
AU - Sokol, Lubomir
AU - Pinilla-Ibarz, Javier
AU - Sotomayor, Eduardo M.
PY - 2011/6
Y1 - 2011/6
N2 - Background: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials. Patients and Methods: We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004. Results: We identified 59,728 patients (mean age, 63 years; 54.4% men, 86.7% white) and had staging information for 57%, including 30% early-stage (I/II) and 27% advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P <.005). For the period from 2000 to 2004, 4-year OS was 46%. Outcome was better in white patients than in black (47 months versus 29 months) (P =.001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years. Conclusion: The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.
AB - Background: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials. Patients and Methods: We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004. Results: We identified 59,728 patients (mean age, 63 years; 54.4% men, 86.7% white) and had staging information for 57%, including 30% early-stage (I/II) and 27% advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P <.005). For the period from 2000 to 2004, 4-year OS was 46%. Outcome was better in white patients than in black (47 months versus 29 months) (P =.001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years. Conclusion: The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.
KW - Diffuse large B-cell lymphoma
KW - Non-Hodgkin lymphoma
KW - SEER
UR - http://www.scopus.com/inward/record.url?scp=80053375056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053375056&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2011.03.012
DO - 10.1016/j.clml.2011.03.012
M3 - Article
C2 - 21658652
AN - SCOPUS:80053375056
SN - 2152-2669
VL - 11
SP - 257
EP - 260
JO - Clinical Lymphoma
JF - Clinical Lymphoma
IS - 3
ER -